The Office of Technology Commercialization (OTC) at Nationwide Children's Hospital and its expert team facilitate the transfer of innovative technologies and research ranging from new therapeutics — including the recently approved, first-of-their-kind gene therapies Zolgensma and ELEVIDYS, FDA-approved treatments for Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD) — to biomarkers, diagnostic tools and clinical tools — such as the Comfort Collar, designed to prevent pressure wounds around tracheostomy tubes — to outside partners to benefit patients, the local community and the general public. As a result, Nationwide Children’s Hospital has earned its reputation as an institution with a remarkable track record of moving discoveries into the marketplace. And the hospital’s physicians and researchers haven’t slowed down in their quest to bring more life-saving therapies to children everywhere.
External link for Office of Technology Commercialization at Nationwide Children's Hospital
We want your feedback! What is the most important type of content for you to see on our LinkedIn page? 1- Research Highlights/Licensing Opportunities – Technology Spotlights 2- Metrics – By The Numbers 3- Events - Conference Spotlights 4- Awards/Honors If there is something else you want to see, let us know in the comments!
This content isn’t available here
Access this content and more in the LinkedIn app
Nationwide Children's Hospital has been named first on Forbes 2024 list of “America’s Best Employers for Women!" Nationwide Children's was recognized as number one among 600 companies based on a survey of 150,000 women working for companies with at least 1,000 employees in the United States. The OTC’s astonishing achievements and growth would not have been possible without the phenomenal women of the OTC! Margaret Barkett, PhD – Director of Licensing Susannah Wolman – Operations and Business Manager Jocelyn Eidahl, PhD – Senior Licensing Associate Ellen Zalucha, PhD, – Licensing Associate Akua Ofori – Agreements Assistant Patricia Lige – Finance Coordinator Geena Licata – Senior IP Coordinator Deborah Lewis – Senior IP Coordinator Andrea Strang - IP Coordinator
We're excited to announce that Nationwide Children's Hospital has been named first on Forbes 2024 list of “America’s Best Employers for Women!" Nationwide Children's was recognized as number one among 600 companies based on a survey of 150,000 women working for companies with at least 1,000 employees in the United States. “Nationwide Children’s Hospital was founded by a group of dedicated women volunteers in 1892. Today, 132 years later, the hospital is still being driven forward by amazing women." - Lorina Wise, chief human resources officer Interested in career opportunities with us? You can learn more at https://bit.ly/2KEygCz #JoinNCH
The Office of Data Sciences at Nationwide Children's Hospital is the proud recipient of the Advanced ML tier in the precisionFDA Automated Machine Learning (AutoML) App-a-thon Challenge: Democratizing and Demystifying Artificial Intelligence! The team assessed numerous AutoML technologies to determine the best approach for biomedical data analysis. In doing so, they thrived in developing an app that allows non-data science experts to input data and define simple guidelines for the required model. The result was an effective application model that precisely anticipated survival outcomes for brain cancer samples and identified sample swaps in the proteomics data. Congratulations to the following! 🏆 Ashley Kubatko - Team lead (director, Office of Data Sciences Sciences Strategy and Operations Team) 🏆 Ben Knutson and Jordan Wells – AutoML App developers (Office of Data Sciences data sciences software engineers) 🏆 Walden Li and Meena Punniaraj – Research and evaluation (UI/UX developer and Software QC specialist, respectively) 🏆 Jeff Gaither and Christopher Bartlett, PhD, MHA – ML and data science (Office of Data Sciences senior data scientist and associate chief of the Office of Data Sciences, respectively) 🏆 Grant Lammi – Technology advisor (director, Office of Data Sciences Cloud Solution Team) 🏆 Lori Peacock, PMP – Project management 🏆 Peter White – Chief data sciences officer, Abigail Wexner Research Institute at Nationwide Children’s Hospital Click here for more: https://bit.ly/3A5VkmN #GuidingIdeasToSolutions #InnovateWithUs #LifeAtNCH #Research #MachineLearning
To our new followers, welcome! Thank you for coming along with us on our journey as we showcase stories of our innovative technologies, innovators, industry partners, and supportive ecosystem! Today, we look back at our 2024 Technology Showcase as a packed Conference Center was treated to six presentations highlighting impactful innovations, novel interventions and new startup companies generated from the Abigail Wexner Research Institute at Nationwide Children's Hospital. A panel of industry experts then discussed the recently developed Midwest Pediatric Device Consortium (MPDC) and ways to accelerate pediatric #meddevice opportunities and development. If you were unable to attend in person or virtually, click here to view the Technology Showcase in its entirety: https://bit.ly/49vFdMf For more on the MPDC, click here: https://bit.ly/4axRVuH #GuidingIdeasToSolutions #InnovateWithUs #MedDevices #Pharmaceuticals #Therapeutics #CRISPR #Research #GeneTherapy #LifeAtNCH
Sudarshan Jadcherla, MD, is a principal investigator with the Center for Perinatal Research and Medical Director of the Neonatal and Infant Feeding Disorders Program at Nationwide Children's Hospital. His research focuses on maturational and dysfunctional mechanisms of neonatal feeding and aero-digestive disorders. The Parent-Implemented Oral Nutrition, Eating and Esophageal Regulation (PIONEER) Products enhance the development of oral-pharyngeal-esophageal motility in infants. This technology (2022-044) is a novel approach for training muscles in non-verbal patients, including neonates, infants, and individuals who have lost skills due to stroke, trauma, or developmental neuropathology. Unlike existing methods, these products stimulate muscles involved in esophageal peristalsis and airway protection without electrical stimulation. By engaging and pre-conditioning select muscles and nerves, the approach helps prevent developmental delays and chronic eating and swallowing difficulties. RINCH has filed a patent application (PCT/US23/81696) and Dr. Jadcherla is continuing to conduct clinical investigations. For more on Dr. Jadcherla’s work, including how his personalized feeding therapy for a neonatal feeding disorder saved an infant’s life, click here: https://bit.ly/4d7BANU We are excited to add that this technology is available for licensing! For more information, please contact licensing associate Ellen Zalucha, PhD. #GuidingIdeasToSolutions #InnovateWithUs #TechTransferTeam #Research
On Tuesday, July 30, Meisam Naeimi Kararoudi, DMV, PhD, will speak at the 5th Annual Gamma Delta T Therapies Summit in Boston, Massachusetts! Dr. Kararoudi will share insights regarding his lab’s novel technology generating off-the-shelf CAR-gdT cells using CRISPR and AAV. “We believe our technology will improve the accessibility issue of the CAR-T cells. We have a mission to provide affordable CAR-T cells anywhere in the world, in particular, in low-to-middle-income countries. I am proud of my team working hard to bring this to a reality.” For more on the summit, click here: https://bit.ly/3Wh8d6j Learn more about Dr. Kararoudi’s work at Nationwide Children's Hospital: https://bit.ly/3JELeLd #GuidingIdeasToSolutions #InnovateWithUs #LifeAtNCH #CARTx #GeneTherapy
We are honored to share that Columbus Business First awarded the Nationwide Children's Hospital Research Building 4, now named the Joe and Linda Chlapaty Research Building, as Best New Medical Project! To view the complete list of our region's best new real estate projects, click here: https://bit.ly/3WgFFK4 #GuidingIdeasToSolutions #InnovateWithUs #Research #LifeAtNCH
Our annual publication, Transfer to Transform (T2T) shares the story of technology commercialization at Nationwide Children's Hospital — a story of bold thinkers, exciting new technologies and job-producing startups! We are excited to share our 2024 T2T, including the following features and exclusive content: 💡 Innovative Approaches to Patient Care 💡 Gene Therapy for the Masses? 💡 Hear Me Read: Novel Technology Approach to Reading Skills for Children with Impaired Hearing 💡 A New Catalyst for Pediatric Device Development 💡 Meet Daphne©, a ChatBot for Pediatric Health Care If you haven't already, be sure to view and download our 2024 T2T! https://bit.ly/3muCqiM #GuidingIdeasToSolutions #LifeAtNCH #InnovateWithUs #TechTransferTeam #Research #GeneTherapy
Please join us in congratulating Scott Q Harper, and lab, as their new paper was published by Molecular Therapy Methods and Clinical Development. This study, entitled "A Self-Complementary AAV Proviral Plasmid System to Reduce Aberrant Cross-Packaging and ITR Promoter Activity in AAV Vector Preparations" details an improved method to manufacture potentially safer AAV for gene therapy. To view the final accepted (pre-proof) manuscript, click here: https://bit.ly/4cNz8MD Adeno-associated viral vectors (AAV) are a leading delivery system for gene therapy in animal models and humans. With several FDA-approved AAV gene therapies on the market, issues related to vector manufacturing have become increasingly important. One such issue relates to the purity of recombinant genomes present in any vector product. Specifically, achieving 100% genome purity in AAV preps is currently impossible. High quality AAV preps may contain a majority of correctly packaged genomes, but essentially all also have a small percentage of packaged DNA contaminants. Gene therapy experts at Nationwide Children's Hospital have developed a novel AAV proviral plasmid that significantly reduces the cross-packaging of bacterial DNA in AAVs, increases correctly packaged AAV payloads, and blunts the ITR promoter to limit the transcription of potentially toxic bacterial open reading frames into the payload. This novel AAV proviral plasmid has the potential to produce safer AAV payloads and limit immunostimulatory effects. We are excited to share that this technology (2024-026: AAV Vector Manufacturing Using a Novel AAV Proviral Plasmid): is currently available for licensing! Please contact senior licensing associate, Jocelyn Eidahl, PhD, for more information. #GuidingIdeasToSolutions #InnovateWiithUs #GeneTherapy #Research